Abstract
Cyclosporin A (CsA) is used to prevent rejection in transplantation and to treat autoimmune and hematologic diseases such as aplastic anemia. However, the tumor growth-promoting effect of CsA remains controversial. We report the case of a 24-year-old man who developed acute lymphoblastic leukemia of precursor-T-cell origin after 75 months of treatment with CsA for aplastic anemia. The surface antigen phenotype of his leukemic cells was CD2+, CD3+, CD5+, CD7+, CD4−, CD8−, CD10−, CD20−, CD34−, CD41−, and CD56−. Southern blot analysis revealed a monoclonal rearrangement of T-cell receptor—J nongermline fragments inHindIII digestion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism.Nature. 1999;397:530–534.
Penn I. Cancers following cyclosporine therapy.Transplantation. 1987;43:32–35.
London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients.Lancet. 1995;346:403–406.
van den Borne BEEM, Landewe RBM, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.Arthritis Rheum. 1998;41:1930–1937.
De Planque MM, Bacigalupo A, Wursch A, et al. Long-term follow-up of severe aplastic anemia patients treated with antithymocyte globulin.Brit J Haematol. 1989;73:121–126.
Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia.New Engl J Med. 1993;329:1152–1157.
Tooze JA, Marsh JCW, Gordon-Smith EC. Clonal evolution of aplastic anaemia to myelodysplastic/acute myeloid leukemia and paroxysmal nocturnal haemoglobinuria.Leuk Lymphoma. 1999;33:231–241.
de Planque MM, Kluin-Nelemans HC, van Krieken HJ. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults.Brit J Haematol. 1988;70:55–62.
Kahan BD. Cyclosporine.New Engl J Med. 1989;321:1725–1738.
Ohhara A, Kojima S, Hamajim N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.Blood. 1997;90:1009–1013.
Sarangi JN, Kashyap R, Choudhry VP, et al. Severe aplastic anemia evolving into T cell acute lymphoblastic leukemia [letter].Eur J Haematol. 1999;63:269–271.
Takeuchi M, Soda R, Takahashi K, et al. Philadelphia chromosome positive acute lymphocytic leukemia arising from aplastic anemia [letter].Am J Hematol. 2000;63:161–162.
Suthanthiran M, Strom TB. Renal transplantation.New Engl J Med. 1994;331:365–375.
Welch DR, Farba A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.Proc Natl Acad Sci U S A. 1990;87:7678–7682.
Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1.J Cell Biol. 1992;18:715–726.
Caulin C, Scholl FG, Frontelo P, Gamallo C, Quantanilla M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype.Cell Growth Differ. 1995;6:1027–1035.
Cui W, Fowlis DJ, Bryson S, et al. TGF β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice.Cell. 1996;86:531–542.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hirose, Y., Masaki, Y., Ebata, K. et al. T-Cell Type Acute Lymphoblastic Leukemia Following Cyclosporin A Therapy for Aplastic Anemia. Int J Hematol 73, 226–229 (2001). https://doi.org/10.1007/BF02981942
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02981942